- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03904628
Phase I Clinical Study of Oral TG02 Capsule in the Treatment of Recurrent / Progressive High-grade Glioma Patients
April 13, 2020 updated by: Lee's Pharmaceutical Limited
Single-center, Dose Escalation, Open Phase I Clinical Study of Oral TG02 Capsule in the Treatment of Recurrent / Progressive High-grade Glioma Patients With Failed TMZ Treatment
The aim of the study was to explore the dose-limiting toxicity (DLT) and the maximum tolerable dose (MTD) of oral administration of TG02 capsules twice a week for 4 weeks.
Study Overview
Status
Unknown
Conditions
Detailed Description
Using the traditional 3 +3 design, 150 mg as the initial dose and 50 mg as the increasing interval of up to 250 mg, and oral administration on the 1st, 4th, 8th, 11th, 15th, 18th, 22nd and 25th day of each 28-day cycle.
Phase I clinical study to evaluate the tolerance and pharmacokinetic parameters of oral TG02 capsules.
Study Type
Interventional
Enrollment (Anticipated)
15
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Zhongping Chen, doctor
- Phone Number: +8613500002457
- Email: chenzhp@sysucc.org.cn
Study Contact Backup
- Name: Zhengzheng Guo, doctor
- Phone Number: +8613580332120
- Email: guochch@sysucc.org.cn
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510000
- Recruiting
- Sun Yat-sen University Cancer Center
-
Contact:
- Zhongping Chen, doctor
- Phone Number: +8613500002457
- Email: chenzhp@sysucc.org.cn
-
Contact:
- Zhengzheng Guo, doctor
- Phone Number: +8613580332120
- Email: guochch@sysucc.org.cn
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion criteria:
- Age: 18 ~ 75 years old, both men and women.
- Histologically proven glioblastoma or anaplastic astrocytoma that has failed from temozolomide treatment in the past.
- According to RANO criteria, patients with clinically evaluated recurrence or progression with clearly measurable lesions.
- If previous radiotherapy has been performed, it must be completed for a period of more than 3 months, or within 3 months but tumor progression occurs in the original radiation field or has been confirmed by histopathology. .
- The first day of treatment was ≥ 2 weeks from the second surgery of recurrence, and the incision is healed in grade A.
- ECOG 0 - 2 points, can swallow the drug and maintain oral administration.
- The expected survival time was more than 3 months.
- The hematopoietic function of bone marrow was adequate: ANC≥1.5×109/L,PLT≥100×109/L,Hb≥90 g/L;.
- Patients who had previously undergone surgical resection were able to provide no less than 15 tumor tissue sections and pathological reports for the study.
Exclusion criteria
- Other cytotoxic drugs were received within 28 days prior to the start of the study, or adverse reactions from previous systematic treatment have not recovered (except alopecia and pigmentation).
- Bevacizumab was treated within 6 weeks before the start of the study.
- Previous treatment with carmostine sustained-release implants or intracerebral implantation of radiotherapy.
- A patient with a major seizure that cannot be effectively controlled by drugs.
- MRI examinations cannot be performed (e.g. pacemakers, undesirable metal dentures, etc.).
- Patients with severe impairment of liver and kidney function: ALT ≥ 2.5 ULN,AST ≥ 2.5 ULN in patients without liver metastasis; ALT ≥ 5 ULN,AST ≥ 5 ULN in patients with liver metastasis; Or TBIL ≥ 1.5 ULN, or Cr ≥ 1.5 ULN, or creatinine clearance ≤ 60 ml/ min calculated by Cockcroft-Gault formula;
- Unstable or uncontrollable diseases or conditions related to or affecting cardiac function (e.g. unstable angina pectoris, congestive heart failure [NYHA > II], uncontrolled hypertension [diastolic blood pressure > 85 mmHg; systolic blood pressure >145 mmHg]), arrhythmia or prolonged QTc interval (male > 450 Ms; female > 470ms).
- A history of arterial thromboembolism (such as stroke, transient ischemic attack, or myocardial infarction) within 6 months. Bleeding or hypercoagulable coagulation disorder occurred within 6 months prior to the first day of the study.
- Active peptic ulcer or inflammatory bowel disease.
- Active hepatitis, or HIV, Treponema pallidum infection.
- Pregnant or breastfeeding.
- Subjects who were unable to use adequate contraception during the study and for six months after the end of the study were unable to use adequate contraception.
- Currently participating in another clinical trial or within 30 days of the last administration of the trial drug.
- The subjects had conditions that affected their provision of written informed consent and / or compliance with the research process.
- There were cases in which any other investigator did not consider it appropriate to join the group.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 150 mg, BIW in every 28d
TG02 capsules were given orally at 150 mg on the 1st, 4th, 8th, 11th, 15th, 18th, 22nd and 25th day, every 28 days.
|
TG02 capsules150mg oral administration, BIW in every 28d
TG02 capsules 200mg oral administration, BIW in every 28d
TG02 capsules 250mg oral administration, BIW in every 28d
|
Experimental: 200 mg, BIW in every 28d
TG02 capsules were given orally at 200 mg on the 1st, 4th, 8th, 11th, 15th, 18th, 22nd and 25th day, every 28 days.
|
TG02 capsules150mg oral administration, BIW in every 28d
TG02 capsules 200mg oral administration, BIW in every 28d
TG02 capsules 250mg oral administration, BIW in every 28d
|
Experimental: 250 mg, BIW in every 28d
TG02 capsules were given orally at 250 mg on the 1st, 4th, 8th, 11th, 15th, 18th, 22nd and 25th day, every 28 days.
|
TG02 capsules150mg oral administration, BIW in every 28d
TG02 capsules 200mg oral administration, BIW in every 28d
TG02 capsules 250mg oral administration, BIW in every 28d
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximal tolerable dose(MTD)
Time Frame: 28 days after first dose
|
DLT occurs in less than 1/6 subjects, this lower dose is defined as MTD.
|
28 days after first dose
|
Dose limiting toxicity (DLT)
Time Frame: 28 days after first dose
|
Adverse events of level 3 or above related to the study drug occurring within 28 days after the first dose as assessed by CTCAE v5.0.
|
28 days after first dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall response rate(ORR)
Time Frame: 12 months
|
proportion of patients whose best overall response during their participation in the study is either CR or PR.
The best overall response is the best response recorded from first dose until disease progression.
|
12 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
c-myc expression in tumor tissue
Time Frame: 12 months
|
the relationship between c-myc expression in tumor tissue with the tumor response
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 22, 2019
Primary Completion (Anticipated)
August 1, 2020
Study Completion (Anticipated)
October 31, 2020
Study Registration Dates
First Submitted
April 3, 2019
First Submitted That Met QC Criteria
April 3, 2019
First Posted (Actual)
April 5, 2019
Study Record Updates
Last Update Posted (Actual)
April 14, 2020
Last Update Submitted That Met QC Criteria
April 13, 2020
Last Verified
April 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NTL-LEES-2018-02
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on High-grade Gliomas
-
National Cancer Institute (NCI)CompletedRecurrent High-Grade Gliomas | Malignant Gliomas | Progressive Low-Grade GliomasUnited States
-
National Cancer Institute (NCI)RecruitingGlioma | High Grade Glioma | Malignant Glioma | Gliomas | Low Grade GliomaUnited States
-
Boston Children's HospitalDana-Farber Cancer Institute; National Institute for Biomedical Imaging and...Recruiting
-
WuHuiUnknown
-
Beth Israel Deaconess Medical CenterCompleted
-
National Cancer Institute (NCI)CompletedRecurrent High-Grade Gliomas | Malignant GliomasUnited States
-
Huashan HospitalCompleted
-
Beijing Tiantan HospitalZhongSheng BioTech Inc.RecruitingWHO Grade III Gliomas | WHO Grade IV GliomasChina
-
Gustave Roussy, Cancer Campus, Grand ParisCompletedRefractory Low-grade Gliomas | Recurrent Low-grade GliomasAustria, Italy, France, Denmark, Netherlands, Spain, Switzerland, United Kingdom
-
National Cancer Institute (NCI)Terminated
Clinical Trials on TG02 capsules oral administration, BIW in every 28d
-
Swiss Federal Institute of TechnologyCompletedAnemia | Iron Deficiency Anemia | Iron DeficiencySwitzerland